Caroline Loew - 05 Dec 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Role
Chief Executive Officer, Director
Signature
/s/ Caroline Loew
Issuer symbol
MURA
Transactions as of
05 Dec 2025
Net transactions value
$0
Form type
4
Filing time
05 Dec 2025, 09:10:35 UTC
Previous filing
09 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Loew Caroline Chief Executive Officer, Director C/O MURAL ONCOLOGY PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND /s/ Caroline Loew 05 Dec 2025 0001989488

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MURA Ordinary Shares Disposed to Issuer -293,059 -100% 0 05 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MURA Stock Option (right to buy) Disposed to Issuer -379,690 -100% 0 05 Dec 2025 Ordinary Shares 379,690 $5.48 Direct F3
transaction MURA Stock Option (right to buy) Disposed to Issuer -90,025 -100% 0 05 Dec 2025 Ordinary Shares 90,025 $5.39 Direct F3
transaction MURA Stock Option (right to buy) Disposed to Issuer -134,225 -100% 0 05 Dec 2025 Ordinary Shares 134,225 $3.43 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Caroline Loew is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"), as of December 5, 2025 (the "Effective Time").
F2 Includes the disposition of 220,148 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically cancelled and converted into the right to receive an amount equal to the Scheme Consideration.
F3 Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.